|
Facebook
Twitter
Linkedin
|
 |
 |
 |
 |
Healthcare Company News 
SpectraScience, Inc Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
SpectraScience, Inc Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
Friday, 01 May 2009 04:35 | 
| Company News - SpectraScience, Inc |
SpectraScience, Inc. announced that Iowa's Des Moines Register published an article reporting that LUMA cervical imaging system Enhances Cervical Cancer Exams
SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, announced that Iowa's Des Moines Register published an article reporting that its LUMA cervical imaging system is enhancing the effectiveness of cancer exams at the University of Iowa.
Since Last July, researchers at the University of Iowa have used the LUMA Cervical Imaging System in more than 80 women - in conjunction with standard methods of detecting cervical cancer - to enhance their ability to locate cancer and precancerous disease.
Dr. Colleen Kennedy, primary investigator for the LUMA study at the university, said in the article that, "The hope is that LUMA will aid in the detection of precancer so that we don't have as much cancer and also aid in the detection of cancer so that it's identified early when treatment is better."
The trial at the University of Iowa is expected to be complete in 2010, with analysis from the first year of the study being available in September, according to Kennedy.
Jim Hitchin, CEO of SpectraScience, said, "We are pleased with the progress of the University's study and look forward to the preliminary results this September. We are encouraged to see an increasing level of attention in the healthcare community related to the LUMA cervical imaging system. Each year precancerous cervical tissue goes undiagnosed in 200,000 American women. The LUMA system, which provides an objective method of screening cervical tissue, can help to dramatically reduce this number. We believe this will improve the quality of healthcare to the patient and reduce overall costs by avoiding the expense of treating later stage cancers."
In the article, Kennedy also remarked, "It really doesn't add any discomfort or significant time to the patients. It literally adds maybe two minutes." For the complete article, go to
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
Source: SpectraScience, Inc.
Since Last July, researchers at the University of Iowa have used the LUMA Cervical Imaging System in more than 80 women - in conjunction with standard methods of detecting cervical cancer - to enhance their ability to locate cancer and precancerous disease.
Dr. Colleen Kennedy, primary investigator for the LUMA study at the university, said in the article that, "The hope is that LUMA will aid in the detection of precancer so that we don't have as much cancer and also aid in the detection of cancer so that it's identified early when treatment is better."
The trial at the University of Iowa is expected to be complete in 2010, with analysis from the first year of the study being available in September, according to Kennedy.
Jim Hitchin, CEO of SpectraScience, said, "We are pleased with the progress of the University's study and look forward to the preliminary results this September. We are encouraged to see an increasing level of attention in the healthcare community related to the LUMA cervical imaging system. Each year precancerous cervical tissue goes undiagnosed in 200,000 American women. The LUMA system, which provides an objective method of screening cervical tissue, can help to dramatically reduce this number. We believe this will improve the quality of healthcare to the patient and reduce overall costs by avoiding the expense of treating later stage cancers."
In the article, Kennedy also remarked, "It really doesn't add any discomfort or significant time to the patients. It literally adds maybe two minutes." For the complete article, go to
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
Source: SpectraScience, Inc.
